Here's the latest from Biosensors' link-up with Terumo

Terumo may have its own DES by 2016.

According to Nomura, Biosensors indicated that while licensing revenue from Japan declined in the last quarter due to increased competition, the group believes that licensing revenue should see a recovery as Terumo intensifies its marketing efforts.

Here's more from Nomura:

The key development in its relationship with Terumo is that Terumo will likely launch its own DES in Japan from 2016 when the current agreement with Terumo expires in April 2016.

To facilitate this transition, Terumo and Biosensors have agreed that Biosensors can become a distributor for Terumo in Japan for the Nobori stent. This will allow Biosensors to set up its own marketing infrastructure in Japan leading up to the expiry of the licensing agreement in 2016.

As a “distributor” for Terumo, Biosensors’ management believes that it will be able to access hospitals in Japan not currently served by Terumo. Terumo has also undertaken to help Biosensors secure approval in Japan for a stent of its choice, which we believe will be BioFreedom.

As for the licensing arrangement with Terumo for territories outside of Japan, Terumo will have to pay a minimum licensing fee based on the amount paid in the last financial year. This arrangement will last until 2014.

We believe this transition arrangement is a win-win for both Terumo and Biosensors in that Terumo will after 2016 be able to launch its own stents while Biosensors will be able to build a long-term presence in Japan for its DES business.

In addition to licensing its DES to Terumo, Biosensors currently already sells its bare metal stents in Japan through its own marketing infrastructure.

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia